Relapse of AML after Allo-SCT is treated with one or more of the following: withdrawal of immunosuppression, salvage chemotherapy, second transplantation and donor leukocyte infusions. The outcome is usually unsatisfactory.
Treatment with the immunomodulating agent lenalidomide results in high response rates in patients with low-risk myelodysplastic syndrome with del(5)(q13q33). 1 Although there are three published case reports of the successful use of lenalidomide as initial therapy for AML with del(5)(q13q33), there are no reported results of its use in relapse after transplantation; a clinical situation in which immunomodulatory agents may have unpredictable effects.
A 65-year-old woman was diagnosed to have AML based on a marrow that was 80% cellular with 24% blasts. Cytogenetic studies showed del(5)(q13q33) and del (22)(q11.2) in 20 of 20 metaphases. She achieved a CR with one course of cytarabine and idarubicin (7 þ 3). After one course of cytarabine consolidation, she underwent an allograft from a 10 of 10 allele-matched unrelated donor. The preparative regimen was low-targeted BU (targeted steady-state concentration 650 ng/ml averaged over 4 days) and CY 60 mg/kg per day for 2 days. This was followed by infusion of PBSCs (6.99 Â 10 6 CD34 þ cells/kg). MTX and tacrolimus were used for GVHD prophylaxis. Her posttransplantation course was complicated by grade II acute GVHD of the skin that resolved with topical therapy. By day 100 post-transplantation, she had achieved 98% donor-type chimerism in the BM and the peripheral blood T cell population (confidence interval ±1%).
On day 371 post-transplantation, she was found to have decreasing blood counts and 4% circulating blasts. A repeat marrow showed 57% blasts with a similar immunophenotype to those at diagnosis. Cytogenetic testing showed del (5)(q13q33) and t(16;22)(q13q11.2) in 13 of 18 metaphases. Fluorescent in situ hybridization for a 5q31 deletion was positive in 42 of 200 cells scored. Her estimated creatinine clearance was 55 ml/min per 1.73 m 2 . At that time, her immunosuppression consisted of tacrolimus alone, and this was tapered off over the subsequent month. At that time, she was begun on oral lenalidomide 10 mg daily. The initiation of this therapy had been delayed because of problems with insurance approval. Over the next month, her blood counts decreased significantly requiring packed red blood cells (PRBC) and platelet transfusions.
At 4 weeks after initiation of lenalidomide, she developed a diffuse erythematous rash involving the trunk and proximal extremities associated with some mild diarrhea. Skin biopsy was non-specific, and she was again treated with topical steroids with complete resolution. By 10 weeks post-treatment, her blood counts were normal. A repeat marrow examination at 12 weeks after treatment initiation showed a complete morphological remission with normal cytogenetics and a negative fluorescent in situ hybridization for 5q31. She is continuing on lenalidomide maintenance and remains in complete clinical remission now after 5 months of therapy.
Three recent case reports have described the successful induction of CR or near-CR with lenalidomide as initial therapy for patients with AML and del(5)(q13q33). Two of these patients had secondary AML evolving from myelodysplastic syndrome, 2,3 whereas a third had de novo AML. 4 All patients received 10 mg lenalidomide daily. However, ours is the first report to describe the successful use of lenalidomide as salvage therapy of relapse after an allograft.
The time course of response in our patient is similar to the other reported cases. In our and the other patients, blood counts normalized after 2-3 months of therapy except for one case in which therapy had been interrupted for pancytopenia. Thus, the best strategy for treating patients similar to ours may be the continuation of lenalidomide through the cytopenias.
A concern with the post-transplantation administration of immunomodulatory agents such as lenalidomide is the possible reactivation or exacerbation of acute GVHD. In post-transplantation patients with myeloma, thalidomide was recently reported to have reactivated GVHD in 5 of 31 patients and lenalidomide in 5 of 13 patients, the latter receiving a dose of 25 mg/day. 5, 6 GVHD reactivation was associated with a response in these patients, but the higher dose of lenalidomide resulted in some GVHD-related deaths. Our patient's course suggests that a mild and transient GVHD reactivation may have occurred, although we were unable to unequivocally show this. Thus, 10 mg/ day may be the optimal initial dose for future patients with del(5)(q13q33) AML who relapse post transplantation.
The curative potential and overall prognosis for posttransplantation patients with del(5)(q13q33) AML who have achieved a remission on lenalidomide are uncertain. One of the previously reported non-transplant cases progressed on maintenance therapy at 5 months, 2 whereas another remains in apparent clinical remission at 1.5 years. 4 Thus, it remains to be determined whether additional therapy, such as donor leukocyte infusions, should be considered in our patient in addition to lenalidomide maintenance or whether the immunomodulatory effects of lenalidomide may sufficiently augment a potentially curative GVL reaction.
Our case suggests that lenalidomide may be considered for patients with del(5)(q13q33)-positive AML, with or without additional cytogenetic abnormalities, who relapse post transplantation. In addition, lenalidomide might also be considered for patients with trisomy 13 7 and perhaps other lenalidomide-sensitive subgroups yet to be determined.
Conflict of interest
CD Ford is a member of the Celgene Speakers Bureau. The remaining authors declare no conflict of interest.
CD Ford, J Asch, K Konopa and FB Petersen Intermountain Blood and Marrow Transplant Program, LDS Hospital, Salt Lake City, UT, USA E-mail: clyde.ford@imail.org
